Literature DB >> 8058168

Practice advisory on selection of patients with multiple sclerosis for treatment with Betaseron. Report of the Quality Standards Subcommittee of the American Academy of Neurology.

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8058168     DOI: 10.1212/wnl.44.8.1537

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  6 in total

Review 1.  Escalating immunotherapy of multiple sclerosis--new aspects and practical application.

Authors:  P Rieckmann; K V Toyka; C Bassetti; K Beer; S Beer; U Buettner; M Chofflon; M Götschi-Fuchs; K Hess; L Kappos; J Kesselring; N Goebels; H-P Ludin; H Mattle; M Schluep; C Vaney; U Baumhackl; T Berger; F Deisenhammer; F Fazekas; M Freimüller; H Kollegger; W Kristoferitsch; H Lassmann; H Markut; S Strasser-Fuchs; K Vass; H Altenkirch; S Bamborschke; K Baum; R Benecke; W Brück; D Dommasch; W G Elias; A Gass; W Gehlen; J Haas; G Haferkamp; F Hanefeld; H-P Hartung; C Heesen; F Heidenreich; R Heitmann; B Hemmer; T Hense; R Hohlfeld; R W C Janzen; G Japp; S Jung; E Jügelt; J Koehler; W Kölmel; N König; K Lowitzsch; U Manegold; A Melms; J Mertin; P Oschmann; H-F Petereit; M Pette; D Pöhlau; D Pohl; S Poser; M Sailer; S Schmidt; G Schock; M Schulz; S Schwarz; D Seidel; N Sommer; M Stangel; E Stark; A Steinbrecher; H Tumani; R Voltz; F Weber; W Weinrich; R Weissert; H Wiendl; H Wiethölter; U Wildemann; U K Zettl; F Zipp; R Zschenderlein; G Izquierdo; A Kirjazovas; L Packauskas; D Miller; B Koncan Vracko; A Millers; A Orologas; M Panellus; C J M Sindic; M Bratic; A Svraka; N R Vella; Z Stelmasiak; K Selmaj; H Bartosik-Psujik; K Mitosek-Szewczyk; E Belniak; A Mochecka; A Bayas; A Chan; P Flachenecker; R Gold; B Kallmann; V Leussink; M Mäurer; K Ruprecht; G Stoll; F X Weilbach
Journal:  J Neurol       Date:  2004-11       Impact factor: 4.849

Review 2.  Managing the adverse effects of interferon-beta therapy in multiple sclerosis.

Authors:  A Bayas; P Rieckmann
Journal:  Drug Saf       Date:  2000-02       Impact factor: 5.606

Review 3.  Newer versus older treatments for relapsing-remitting multiple sclerosis.

Authors:  B Weinstock-Guttman; J A Cohen
Journal:  Drug Saf       Date:  1996-02       Impact factor: 5.606

4.  Prescribing recommendations for interferon-Beta in multiple sclerosis.

Authors:  B Weinstock-Guttman; R A Rudick
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

Review 5.  Choosing drug therapy for multiple sclerosis. An update.

Authors:  B W van Oosten; L Truyen; F Barkhof; C H Polman
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

6.  Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing-remitting multiple sclerosis?

Authors:  Zsolt Mezei; Daniel Bereczki; Lilla Racz; Laszlo Csiba; Tünde Csepany
Journal:  Neuropsychiatr Dis Treat       Date:  2012-10-23       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.